Myclausen 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0054/G 
This was an application for a group of variations. 
01/08/2022 
SmPC and PL 
Section 5.1 of the SmPC has been updated based on a 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
literature review on mycophenolate mechanism of action.  
Section 5.2 of the SmPC has been updated to add new 
information to the Distribution and Elimination subsections.  
Sections 4.5 and 5.2 of the SmPC have been updated to 
amend the existing information on patients taking oral 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
new additional data is required to be submitted by 
contraceptives.  
Section 2 of the Package Leaflet has been updated to align 
the wording of the text with the SmPC section 4.4. 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
PSUSA/10550
Periodic Safety Update EU Single assessment - 
16/12/2021 
16/02/2022 
PL 
Refer to Scientific conclusions and grounds recommending 
/202105 
mycophenolate mofetil, mycophenolic acid 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10550/202105. 
Page 2/14 
 
 
 
 
 
 
 
IA/0053 
B.III.1.a.2 - Submission of a new/updated or 
24/08/2021 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0051 
C.I.2.a - Change in the SPC, Labelling or PL of a 
16/07/2021 
16/02/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
PSUSA/10550
Periodic Safety Update EU Single assessment - 
10/12/2020 
18/02/2021 
SmPC 
Refer to Scientific conclusions and grounds recommending 
/202005 
mycophenolate mofetil, mycophenolic acid 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10550/202005. 
IA/0050/G 
This was an application for a group of variations. 
23/12/2020 
n/a 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.II.b.2.a - Change to importer, batch release 
Page 3/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IA/0048 
A.5.b - Administrative change - Change in the name 
29/01/2020 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
PSUSA/10550
Periodic Safety Update EU Single assessment - 
28/11/2019 
n/a 
PRAC Recommendation - maintenance 
/201905 
mycophenolate mofetil, mycophenolic acid 
IB/0046/G 
This was an application for a group of variations. 
17/04/2019 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IA/0045/G 
This was an application for a group of variations. 
19/03/2019 
n/a 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
Page 4/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Page 5/14 
 
 
 
 
 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
PSUSA/10550
Periodic Safety Update EU Single assessment - 
29/11/2018 
n/a 
PRAC Recommendation - maintenance 
/201805 
mycophenolate mofetil, mycophenolic acid 
IA/0044 
B.III.1.a.2 - Submission of a new/updated or 
20/11/2018 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
PSUSA/10550
Periodic Safety Update EU Single assessment - 
14/12/2017 
05/03/2018 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201705 
mycophenolate mofetil, mycophenolic acid 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10550/201705. 
IA/0042/G 
This was an application for a group of variations. 
26/10/2017 
n/a 
B.II.c.1.b - Change in the specification parameters 
and/or limits of an excipient - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.II.c.1.b - Change in the specification parameters 
and/or limits of an excipient - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.II.c.2.a - Change in test procedure for an excipient 
- Minor changes to an approved test procedure 
B.II.c.2.a - Change in test procedure for an excipient 
Page 6/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- Minor changes to an approved test procedure 
B.II.c.2.a - Change in test procedure for an excipient 
- Minor changes to an approved test procedure 
B.II.c.2.b - Change in test procedure for an excipient 
- Deletion of a test procedure if an alternative test 
procedure is already authorised 
B.II.c.2.b - Change in test procedure for an excipient 
- Deletion of a test procedure if an alternative test 
procedure is already authorised 
IA/0040/G 
This was an application for a group of variations. 
14/06/2017 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IA/0039 
A.7 - Administrative change - Deletion of 
11/05/2017 
05/03/2018 
Annex II and 
manufacturing sites 
N/0038 
Update of the package leaflet with revised contact 
13/10/2016 
05/03/2018 
details of the local representative for Czech Republic. 
PL 
PL 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
IA/0037 
B.III.1.b.3 - Submission of a new/updated or 
22/07/2016 
n/a 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
Page 7/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturer 
IAIN/0036 
B.II.b.1.a - Replacement or addition of a 
03/06/2016 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0035 
B.II.b.2.c.1 - Change to importer, batch release 
18/03/2016 
12/08/2016 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0033 
C.I.2.a - Change in the SPC, Labelling or PL of a 
08/02/2016 
12/08/2016 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II and PL 
IAIN/0034 
C.I.8.a - Introduction of or changes to a summary of 
22/12/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IAIN/0032 
A.1 - Administrative change - Change in the name 
14/12/2015 
12/08/2016 
SmPC, 
and/or address of the MAH 
Labelling and 
PL 
IB/0031/G 
This was an application for a group of variations. 
18/08/2015 
12/08/2016 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
Page 8/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0030 
A.1 - Administrative change - Change in the name 
12/08/2015 
12/08/2016 
SmPC, 
and/or address of the MAH 
Labelling and 
PL 
IA/0029 
A.5.b - Administrative change - Change in the name 
16/07/2015 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
Page 9/14 
 
 
 
 
 
 
 
 
 
 
 
R/0023 
Renewal of the marketing authorisation. 
26/03/2015 
27/05/2015 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
including all variations introduced since the marketing 
and PL 
authorisation was granted, the CHMP considered that the 
benefit-risk balance of Myclausen in the approved 
indications remains favourable and therefore recommended 
the renewal of the marketing authorisation with unlimited 
validity. 
IB/0028 
C.I.2.a - Change in the SPC, Labelling or PL of a 
29/01/2015 
27/05/2015 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0027 
B.III.1.b.3 - Submission of a new/updated or 
23/12/2014 
n/a 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
IA/0025/G 
This was an application for a group of variations. 
23/12/2014 
n/a 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
Page 10/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0026 
B.III.1.a.2 - Submission of a new/updated or 
22/12/2014 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IA/0024 
B.III.1.a.2 - Submission of a new/updated or 
22/12/2014 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IA/0022/G 
This was an application for a group of variations. 
24/10/2014 
27/05/2015 
Annex II and 
PL 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
N/0021 
Minor change in labelling or package leaflet not 
24/04/2014 
27/10/2014 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0020 
C.I.2.a - Change in the SPC, Labelling or PL of a 
30/10/2013 
27/10/2014 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
II, Labelling 
and PL 
Page 11/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the MAH 
IB/0019 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
21/10/2013 
27/10/2014 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IAIN/0018 
B.II.b.1.a - Replacement or addition of a 
11/09/2013 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0017 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/09/2012 
29/10/2012 
SmPC and PL 
Update of Section 4.5 of the SmPC to include information 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
regarding the interaction with proton pump inhibitors 
following the outcome of PSUR 18 assessment (covering 
period: 01.05.08-30.04.11) of the Reference Product. The 
Package Leaflet has been updated accordingly. The MAH 
also took the opportunity to introduce minor linguistic 
amendments in the Danish, Finish, Norwegian and Swedish 
PI. 
IAIN/0016/G 
This was an application for a group of variations. 
10/09/2012 
n/a 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
IB/0015 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
16/12/2011 
28/06/2012 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
N/0014 
Minor change in labelling or package leaflet not 
25/10/2011 
n/a 
PL 
connected with the SPC (Art. 61.3 Notification) 
Page 12/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X/0003 
To register a new pharmaceutical form and strength 
21/07/2011 
16/09/2011 
SmPC, 
250 mg hard capsules 
Labelling and 
PL 
PL 
PL 
Annex I_2.(d) Change or addition of a new 
pharmaceutical form 
N/0013 
Minor change in labelling or package leaflet not 
09/06/2011 
n/a 
connected with the SPC (Art. 61.3 Notification) 
N/0012 
Minor change in labelling or package leaflet not 
05/04/2011 
n/a 
connected with the SPC (Art. 61.3 Notification) 
IA/0010 
B.II.b.2.a - Change to batch release arrangements 
15/03/2011 
n/a 
and quality control testing of the FP - Replacement 
or addition of a site where batch control/testing 
takes place 
IA/0009 
B.II.b.2.a - Change to batch release arrangements 
15/03/2011 
n/a 
and quality control testing of the FP - Replacement 
or addition of a site where batch control/testing 
takes place 
IA/0006 
B.II.b.2.b.1 - Change to batch release arrangements 
15/03/2011 
n/a 
Annex II and 
and quality control testing of the FP - Not including 
PL 
batch control/testing 
IA/0005 
B.II.b.2.b.1 - Change to batch release arrangements 
15/03/2011 
n/a 
Annex II and 
and quality control testing of the FP - Not including 
PL 
batch control/testing 
Page 13/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0004 
B.III.1.a.3 - Submission of a new or updated Ph. Eur. 
15/03/2011 
n/a 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - New certificate from a new 
manufacturer (replacement or addition) 
IA/0011 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
11/03/2011 
n/a 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - Updated certificate from an already 
approved manufacturer 
IA/0008 
B.II.b.1.a - Replacement or addition of a 
11/03/2011 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IA/0007 
B.II.b.1.a - Replacement or addition of a 
11/03/2011 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0001 
C.I.3.a - Implementation of change(s) requested 
19/01/2011 
n/a 
PL 
Changes to the PIL section 2. BEFORE YOU TAKE 
following the assessment of an USR, class labelling, a 
PSUR, RMP, FUM/SO, data submitted under A 45/46, 
or amendments to reflect a Core SPC - Changes with 
NO new additional data are submitted by the MAH 
MYCLAUSEN - Take special care with Myclausen and 
Pregnancy and breast-feeding recommended by the CHMP 
following the assessment of the originator product. 
IA/0002 
B.II.b.1.a - Replacement or addition of a 
07/01/2011 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
Page 14/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
